ProCE Banner Activity

Expert Guidance and Resources to Personalize Care and Improve Outcomes for Patients With RCC

Text Module

Read as Brian A. Costello, MD, MS, discusses how to personalize care and improve outcomes for patients with advanced renal cell carcinoma.

Released: January 22, 2021

Expiration: January 21, 2022

No longer available for credit.

Share

Faculty

Brian A. Costello

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Learning Objectives


  • Identify patients most likely to benefit from immunotherapy-based combinations, considering risk assessment along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC based on available clinical evidence, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to sequence therapies to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Outline novel combination agents and regimens being investigated in advanced and earlier stages of RCC in clinical trials
  • Manage specific disease-related complications and treatment or adverse events and toxicities commonly associated with approved and investigational therapeutic approaches for advanced RCC

Faculty Disclosure

Primary Author

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Brian A. Costello, MD, MS, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.